Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents...
Year: 2025
Dr. Anosh Ahmed Foundation and CEO: Anosh Ahmed Commits $1M Investment in ReliefWings to Advance Humanitarian Aid
AI-powered drone network aims to deliver food, medicine, and emergency supplies to flood-affected and hard-to-reach communities Anosh Ahmed invests in...
Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE...
CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from...
TOMI Environmental Solutions Announces $175,000 Equipment Purchase by T.A.C.T., Signaling Continued Demand in Commercial Sector
Strategic Expansion with Leading Franchise Network Underscores Revenue Potential and Market Leadership for SteraMist iHP TechnologyFREDERICK, Md., Oct. 01, 2025...
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of...
Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer
Cambridge, UK, 1 October 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G...
Primary.Health Launches Nation’s First Advanced Newborn Screening Case Management Platform
Primary’s cloud-based system modernizes state newborn screening tracking and follow-up, incorporating cutting-edge science, evidence-based clinical protocols, and emerging screening methodologies...
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting...
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical...
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc....
Alignment Health Unveils 2026 Medicare Advantage Plans with Strong Benefits, Expanded Support for Seniors
Plans to reach nearly 8.3 million Medicare-eligible adults across five states during annual enrollment period, Oct. 15-Dec. 7ORANGE, Calif., Oct....
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company...
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
Appointments expand clinical and regulatory capabilities ahead of key program milestonesBOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc.,...
ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors
MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty...
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
CHICAGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for...